XNAS
SNES
Market cap4mUSD
Oct 08, Last price
0.72USD
1D
-5.50%
1Q
-48.36%
Jan 2017
-100.00%
IPO
-100.00%
Name
Senestech Inc
Chart & performance
P/E
—
P/S
1.73
EPS
—
Div yield, %
—
Shrs. gr., 5y
664.80%
Rev. gr., 5y
53.81%
Revenues
2m
+19.60%
Net income
-6m
L+3.22%
CFO
-6m
L-4.69%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
SenesTech, Inc. engages in the development and commercialization of a technology for managing animal pest populations through fertility control. The company offers ContraPest, a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide and triptolide; and Evolve, a soft bait containing the active ingredient, cottonseed oil that limits the reproduction of male and female rats beginning with the first breeding cycles following consumption. It also develops Evolve Mouse, a modified version of its bait technology containing the active ingredient cottonseed oil that limits reproduction of male and female mice. The company was incorporated in 2004 and is headquartered in Surprise, Arizona.
Key people
Thomas C. Chesterman
Chief Financial Officer, Executive Vice President, Treasurer, Assistant Secretary · since 2015
Kim Patrice Wolin
Executive Vice President - Operations, Secretary · since 2014
Jamie Bechtel Morrison
Director · since 2018
Independent Director · since 2016
Independent Director · since 2015
Julia Ann Williams
Independent Director · since 2011
Legal address
c/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
WILMINGTON, DE 19808
US
Headquarters
3140 North Caden Court; Suite 1
Flagstaff, AZ 86004
US
Flagstaff, AZ 86004
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||